Question 57

Diphenoxylate/atropine (Lomotil) is classified as a Schedule V controlled substance.

Diphenoxylate/atropine (Lomotil) is classified as a Schedule V controlled substance due to its lower potential for abuse compared to other schedules. This classification reflects its medical use for treating diarrhea while minimizing the risk of dependency.

A) Schedule II

Schedule II substances are those that have a high potential for abuse and can lead to severe psychological or physical dependence. Diphenoxylate/atropine does not fit this classification as it is recognized for its lower abuse potential and is not associated with severe addiction risks.

B) Schedule III

Schedule III substances have a moderate to low potential for physical and psychological dependence. However, Lomotil's classification as a Schedule V indicates even lower potential for abuse, making this option incorrect.

C) Schedule IV

Schedule IV substances have a lower potential for abuse relative to Schedule III substances but are still higher than those in Schedule V. Diphenoxylate/atropine's categorization as a Schedule V drug highlights its minimal risk compared to Schedule IV options.

D) Schedule V

Schedule V substances are recognized as having the lowest potential for abuse among controlled substances and are typically used for medical purposes with strict regulations. Diphenoxylate/atropine is classified here because it effectively treats diarrhea without significant risk of addiction.

Conclusion

The classification of diphenoxylate/atropine (Lomotil) as a Schedule V controlled substance is justified by its medical utility and low potential for abuse. Other options, including Schedule II, III, and IV, incorrectly reflect a greater potential for dependency than what is evidenced for Lomotil. Thus, Schedule V is the correct classification based on its pharmacological profile and regulatory status.